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Abstract
Vaccine adverse events (VAEs) are adverse bodily changes occurring after vaccination. Understanding the adverse event (AE)
profiles is a crucial step to identify serious AEs. Two different types of seasonal influenza vaccines have been used on the
market: trivalent (killed) inactivated influenza vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV). Different
adverse event profiles induced by these two groups of seasonal influenza vaccines were studied based on the data drawn
from the CDC Vaccine Adverse Event Report System (VAERS). Extracted from VAERS were 37,621 AE reports for four TIVs
(Afluria, Fluarix, Fluvirin, and Fluzone) and 3,707 AE reports for the only LAIV (FluMist). The AE report data were analyzed by
a novel combinatorial, ontology-based detection of AE method (CODAE). CODAE detects AEs using Proportional Reporting
Ratio (PRR), Chi-square significance test, and base level filtration, and groups identified AEs by ontology-based hierarchical
classification. In total, 48 TIV-enriched and 68 LAIV-enriched AEs were identified (PRR.2, Chi-square score .4, and the
number of cases .0.2% of total reports). These AE terms were classified using the Ontology of Adverse Events (OAE),
MedDRA, and SNOMED-CT. The OAE method provided better classification results than the two other methods. Thirteen out
of 48 TIV-enriched AEs were related to neurological and muscular processing such as paralysis, movement disorders, and
muscular weakness. In contrast, 15 out of 68 LAIV-enriched AEs were associated with inflammatory response and respiratory
system disorders. There were evidences of two severe adverse events (Guillain-Barre Syndrome and paralysis) present in TIV.
Although these severe adverse events were at low incidence rate, they were found to be more significantly enriched in TIV-
vaccinated patients than LAIV-vaccinated patients. Therefore, our novel combinatorial bioinformatics analysis discovered
that LAIV had lower chance of inducing these two severe adverse events than TIV. In addition, our meta-analysis found that
all previously reported positive correlation between GBS and influenza vaccine immunization were based on trivalent
influenza vaccines instead of monovalent influenza vaccines.
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Introduction
Vaccination is a highly effective and standardized public health
practice; however, patients may suffer adverse events (AE) in
reaction to the administered vaccine [1]. Some AEs can be serious
(SAE) and even fatal. To monitor post-marketing adverse events
associated with released vaccines, the Centers for Disease Control
and Prevention (CDC) and the Food and Drug Administration
(FDA) established the Vaccine Adverse Event Report System
(VAERS) surveillance program [2]. It is important to note that
adverse event reports in VAERS do not assert causality and,
therefore, are not to be confused with adverse effects, which implies
causal association. The primary strength of VAERS lies in the
national coverage of its reporting network, so that it can pick up a
rare AE incident in a timely manner. VAERS has been used in
many studies that resulted in useful insights of post-vaccination
incidents [3,4,5,6,7].
Since VAERS records contain high-noise data, a well-defined
method is necessary to analyze VAERS entries. The VAERS
reporting protocol is a passive surveillance system that accepts data
from any reporter. Each case report is curated with individual
adverse events manually assigned to the Medical Dictionary for
Regulatory Activities (MedDRA) codes by VAERS personnel.
However, the VAERS data entry process still introduces strong
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biases influenced by over- or under-reported symptoms and signs,
reporters’ inability to assess causality, and temporal association of
the report (e.g., inconclusive symptoms get inserted as post-
vaccination AE). Moreover, there are no denominator data of total
vaccinations for various population groups and specific vaccines;
therefore, incidence rates and relative risks of specific adverse
events cannot be calculated by processing the raw VAERS data
[8]. However, there has been proof of plausibility of utilizing
monitored post-release drug adverse event data with combinato-
rial bioinformatics methods in analyzing the occurrence of serious
events. For example, a Bayesian network approach has been used
to exploit the WHO Uppsala Center drug safety reports’
pharmacovigilance database [9,10]. The Proportional Reporting
Ratio (PRR) and Chi-square significance test methods have been
applied to analyze AE data in the Medicines Control Agency, and
the Drug Safety Research Unit [11,12,13].
The MedDRA system as a coding vocabulary nomenclature has
been widely used by physicians and health care researchers in
annotating AE information. It has played a central role in
standardizing and improving vocabulary in the scope of AE
reporting. However, MedDRA has several issues in domain
completeness and discrepancies with a physician’s AE description
that result from MedDRA’s lack of a well-defined hierarchical
structure [14]. A recent study of the construction of the Ontology
of Adverse Events (OAE; previously known as Adverse Event
Ontology (AEO) [15]) has addressed the issue of information
structure of standardized vocabulary. OAE is a community-based
biomedical ontology for adverse events. Biomedical ontologies are
sets of terms and relations that represent entities in the real world
and how they relate to each other; terms are associated with
documentation and definitions, which are, ideally, expressed in
formal logic to support automated reasoning [16]. OAE is now a
candidate ontology in the Open Biomedical Ontology (OBO)
foundry [17]. In OAE, each AE is considered as a pathological
process that starts at the time of a medical intervention (e.g.,
vaccination) and has the outcome of a symptom (e.g., fever), sign
(e.g., increased blood glucose), or a process (e.g., bacterial infection),
which can be mapped to a MedDRA term. After the OAE-
MedDRA term mapping, the VAERS contents transcribed with
the MedDRA terminology can be analyzed by OAE that organizes
adverse event terms into a logical hierarchical structure based on
pathological processes of the AE symptoms.
Seasonal influenza is a common illness sufficiently fatal that the
CDC Advisory Committee on Immunization Practices (ACIP)
recommends that everyone 6 months of age or older should
receive influenza vaccine every year (http://www.cdc.gov/
mmwr/preview/mmwrhtml/rr59e0729a1.htm). Seasonal influen-
za is different from pandemic influenza, which only happens
approximately every 40 years: 1918, 1957, 1968, and 2009.
However, the risk of post-vaccination serious adverse events
(SAEs), especially Guillain-Barre Syndrome (GBS), must be
considered in making and implementing recommendations for
use of the several types of marketed seasonal influenza vaccines.
Assessing adverse events triggered by different influenza vaccines
can enhance our understanding of vaccine safety.
In this study, we hypothesized that trivalent killed inactivated
influenza vaccines (TIV), and intranasal spray for live attenuated
influenza vaccine (LAIV), the two subtypes of trivalent seasonal
influenza vaccines, induce different types of adverse events. The
rationale behind managing influenza vaccines into two groups is:
1) They are two very different types of vaccines; 2) they both have
been widely used after their releases, and have resulted in a
significant number of adverse event records reported to VAERS;
and 3) both groups of vaccines aim for protection against influenza
A/B, while having different methods of administration (intramus-
cular injection for TIV, and intranasal spray for LAIV. Using a
novel workflow of combinatorial, ontology-based detection of AE
(CODAE) approach, we compared the VAERS clinic-based
adverse event reports associated with these two groups of influenza
vaccines. Our results have confirmed that TIV have a low signaled
incidence rate of GBS and related adverse events such as paralysis
and paresthesias, while recipients of trivalent LAIV have no
statistically significant association with GBS or related neurological
symptoms.
Methods
Adverse Event Data Extraction
Records of post-vaccination adverse events were queried from
the CDC Vaccine Adverse Event Reporting System (VAERS;
access date: May 18th, 2011). The query was constructed to
retrieve adverse event information of killed inactivated vaccines
(TIV group) consisting of Afluria, Fluarix, Fluvirin, and Fluzone, and
live attenuated vaccine (LAIV group) FluMist. The names and the
numbers of AEs for each type of vaccines were summarized. Some
AE symptoms are common in both groups, while a significant
number of symptoms are unique to each cohort. Symptoms from
both AE record tables differ in rankings (number of occurrences)
and the nature of adverse events themselves. We hypothesize that
performing a comparative analysis of different physiological
responses implied by AE symptoms associated with each vaccine
could lead us to understand the underlying response mechanism of
the influenza A/B vaccines.
AE report signal detection with Proportional Reporting
Ratios (PRRs)
Each group of reports (TIV and LAIV) was analyzed
independently with the PRR method (as introduced by Evans et
al. [11]) (Table S1). PRR calculates the proportions of specific
AE(s) for a vaccine (or a group of vaccines) of interest where the
comparator is all other vaccines in the VAERS database.
Therefore, calculations to detect signals from the data pool utilize
the total number of reports for each vaccine as a denominator to
determine the proportion of all reports that fall in the type of
interest (which in this case is the individual AE that was retrieved
by each group of vaccine compared against reports of that
particular AE in the total VAERS database pool). The PRR score
of individual AEs in each group is then used as one of the
composite criteria to compare for significant AEs in each group.
Chi-square test to identify statistically significant AEs
In parallel with PRR signal detection, the Chi-square signifi-
cance test for contingency tables was applied to individual AE
MedDRA terms that are associated with TIV or LAIV indepen-
dently [11]. The Chi-square test computes a Chi-square score and
probability for each AE in each group using a 262 frequency/
contingency table. The 262 contingency table was composed of
four disjoint counts based on the total number of all reports in
each group (37,621 TIV cases, 3,707 LAIV cases) against the
overall VAERS data (616,215 cases). An AE was called significant
when its Chi-square score was greater than 4, which implied P-
value of approximately 0.05 or smaller [11].
AE case report frequency as a cutoff for filtering out
background noise
Besides the PRR calculation and Chi-square test, the screened
PRR method (SPRR) also used a minimal sample size cutoff ([18]
Adverse Events of Influenza Vaccines
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[19]). The original SPRR paper uses a minimal sample size cutoff
of 3 case reports for each AE to be further considered. Such a
constant cutoff does not work for our project since the two groups
(TIV and LAIV) of case reports have different case report sizes. In
our study, the sample size cutoff threshold of the number of reports
for both groups was determined to be 0.2% of the total number of
reports of each group. Using this cutoff, the biological implication
would mean that at least 2 out of 1000 cases reported the AE of
interest. The selection of the cutoff was supported by the report
signal curve on the total case reports for each group (Figure S1 A
and B). In either TIV or LAIV case, the 0.2% cutoff line was able
to cut off many AEs which are in the bottom of the signal curve
and considered as ‘‘noise’’. The cutoff line is located in a similar
pattern in both cases (Figure S1 A and B), suggesting that the 0.2%
cutoff removes ‘‘noise’’ AEs in each group correspondingly. The
number of cases for one AE to get called in for TIV group was
evaluated to be 75 (number of reports . = 75), while the cutoff for
LAIV group was evaluated at 8 (number of reports . = 8).
To determine which AEs were exclusively enriched for TIV or
LAIV, we excluded AEs that appeared as common signals in both
lists. We also excluded ambiguous AEs such as no adverse event, or
those of lab test result normal. We were then left with 48 TIV-
enriched AEs and 68 LAIV-enriched AEs. These are AEs that
their corresponding PRR score is at least 2, and Chi-square is
greater than 4 (approximately of probability value of 0.05 or
smaller).
Comparison of concept reorganization based on
semantic similarity of the Ontology of Adverse Events
(OAE)
The OAE (http://www.oae-ontology.org/) was previously
named the Adverse Event Ontology (AEO) [15]. The change of
the name space was applied to avoid a conflict with another
ontology. OAE was downloaded from http://sourceforge.net/
projects/oae/. OAE was visualized with the Protégé 4.0.2 OWL
editor. For better comparison and analysis, related MedDRA
terms associated with TIV and LAIV were mapped to corre-
sponding OAE terms. However, the ontological structures of these
terms in the two systems are often different. TIV- and LAIV-
related AEs were classified based on the OAE structure hierarchy
for comparative analyses. Specifically, the TIV- and LAIV-specific
AEs and their parent term hierarchies were extracted from the
OAE using the OntoFox program [16]. The hierarchical results
were visualized using the Protégé-OWL editor and manually
studied and compared. To compare the performances of
classification using different ontologies, TIV- and LAIV-specific




Data obtained by clinical observations are often high in
statistical noise, which sometimes leads to temporal associations
that are wrongly believed to be causal [20]. In this study, we
demonstrated that, by combining multiple statistical and bioinfor-
matics methods, background noise and irrelevant information can
be reduced to a minimal level. This also allows a meaningful
interpretation of data. Scientists can draw a sensible hypothesis
from these processed data.
Our Combinatorial Ontology-based Detection of vaccine
Adverse Events method (CODAE) is outlined in Figure 1. The
generalized version of CODAE is for detection of significant AE
terms for one vaccine or one group of vaccines (Figure 1A). As the
first step of CODAE analysis, the information of vaccine-
MedDRA term associations is extracted from a spontaneous AE
reporting system (e.g., VAERS). Then a reliable and robust
bioinformatics method, such as the commonly used Screened
Proportional Reporting Ratio (SPRR) [11,18], can be used to
identify statistically sound AE signals. Then the identified AEs can
be classified using an ontology-based classification method.
The screened PRR (SPRR) methodology is typically used in
detection of vaccine adverse events (VAEs) from spontaneously
reported data. PRR is a component of SPRR for VAE signal
detection [11]. However, an association between a vaccine and
VAE from PRR calculation might not be truly statistically
significant due to the lack of well-defined null distribution [18].
To overcome this concern, SPRR methodology includes an
additional Yates-corrected Chi-square score calculated to detect
the significance level of each AE term in the specific group of
vaccines. A Chi-square score of 3.84 equals to a P-value of 0.05.
Therefore, a Chi-square score of greater than 4 is approximately
equivalent to a P-value of less than 0.05. To ensure the specificity
of the study, SPRR also includes a minimum number of reports as
a filter to eliminate random occurrences. In summary, SPRR uses
the following screening criteria; PRR . = 2, Yates-corrected Chi-
square . = 4, and minimal case report number . = 3 [11].
In our CODAE strategy, we modified the SPRR methodology
[11,18] with an adjustable cutoff for filtering AEs which have a low
number of case reports. In SPRR and previous smaller PRR-based
studies, this cutoff number was recommended to be at least 3
occurrences [11,21]. Since TIV and LAIV are each associated
with a large number of case reports, at a cutoff number of VAERS
reports = 3, the significant AE lists associated with TIV or LAIV
cover hundreds of AEs. Moreover, the case-report populations
vaccinated by TIV and LAIV differ by size. Since one major
objective of our study is to compare the AEs and SAEs
independently induced by TIV and LAIV, we determined that
the number of reports per AE must be at least .0.2% of total
reports, i.e., at least 75 (out of total 37,621) for TIV and 8 (out of
total 3,707) for LAIV. The necessity and accuracy of this setting
are reflected by the large numbers of AEs having low AE
frequencies below the 0.2% cutoff shown in Figure S1. The 0.2%
cutoff provided us better manageability of the sets of AEs studied
in each cohort.
This generalized CODAE workflow (Figure 1A) can be
expanded to analyze and compare AEs associated with two
groups of vaccines such as TIV and LAIV (Figure 1B). In our TIV
and LAIV VAE study, the Chi-square analysis and PRR of each
group were performed separately in parallel with each other.
Those AEs with PRR score greater than 2 and Chi-square score
greater than 4 were kept for further studies. These AEs are
statistically significant, TIV- or LAIV-enriched AEs.
After significant AE signals are detected, we then classified the
signals using an ontology-based method. Each AE signal in
VAERS is represented by a MedDRA term with a unique
identifier. All these MedDRA terms were mapped to specific terms
of the Ontology of Adverse Events (OAE). The OAE hierarchy
was used to classify the AE signals.
Overall results: extracting differential AE profiles from
VAERS TIV and LAIV data
As of May 18, 2011, there were 7,520 MedDRa AE terms and
616,215 VAERS case records (one record may contain multiple
AEs) listed for 75 vaccines reported to VAERS. The two subsets of
seasonal influenza vaccines studied (TIV and LAIV) held 3,582
AE terms in total, and the comparison set contained 37,621 TIV
reports and 3,707 LAIV reports. Following the overall analysis
Adverse Events of Influenza Vaccines
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pipeline (Figure 1), TIV- or LAIV- enriched AEs were determined
by Chi-square score (.4), PRR score (.2), and the number of
reports (0.2% of total reported cases, i.e., . = 75 for TIV and
. = 8 for LAIV).
Figure 2 provides a Venn diagram showing the results after the
three criteria of AE selection were applied in this study. In the TIV
group, 1,236 AEs have their Chi-square scores greater than 4
(labeled as x2(+)), while 2,346 AEs did not pass this condition
(labeled as x2(2)). In terms of PRR analysis, 1083 AEs contained a
PRR score of at least 2 (labeled as PRR(+)), while 2,499 AEs did
not pass the PRR criterion. In total, 271 AEs passed the condition
of sample size of at least 75 (labeled as count(+)), while 3,311 AEs
did not (labeled as count(2)). These numbers indicate that, even
though sample size filtering screened out the majority of the low-
signal AEs, additional filtering by x2 and PRR scoring provided
screening measures that could help detect true signals of enriched
AEs with high significance. Among 271 AEs that passed the
sample size screening, there existed 223 AEs that passed the x2 test
and 128 AEs that passed PRR evaluation. There were 80 AEs that
overlapped within the screening of x2 and PRR tests, leaving 48
AEs out as the result of 3-criteria elimination.
In the LAIV group, 757 AEs passed the x2(+) filtering, 2,825
remained in (x2(2)). Based on frequency filtering, for the PRR
analysis, 898 AEs passed PRR condition (PRR(+)) while 2,684 AEs
were excluded by PRR (PRR(2)). 274 AEs contained at least 8
records per AE (count(+)), and 3,308 were left in count(2) group.
Note that the LAIV cohort had identical screening results with x2
and PRR after the sample size cutoff. This phenomenon was
considered coincidental and did not occur in the TIV case, and
should not suggest that either screening method did not deliver
further or useful filtering.
There were 80 TIV AEs and 118 LAIV AEs that passed all
three conditions with 31 AEs overlapping between the two lists.
After screening out ambiguous or common AE terms, 48 AEs were
included in the TIV analysis, and 68 AEs were included in the
LAIV analysis. Tables 1 and 2 summarize the lists of AEs for TIV
and LAIV that were used for analytical clustering, respectively.
The AEs in these two tables were classified based on an ontological
method using the Ontology of Adverse Events (OAE) (Figure S2).
For comparisons, the classifications of TIV- and LAIV-enriched
AE terms were also generated using MedDRA (Figure S3) and
SNOMED-CT (Figure S4). The enriched AE terms represent
those AE terms that were statistically ‘‘enriched’’ in one group
compared to the other group (P-value ,0.05). The comparison of
the results from these classifications is described in the Discussion
section. Of the three classification systems, the OAE classification
method performed the best for the purpose of classification. This
was considered based on feasibilities of structural organization of
Figure 1. Workflow of the CODAE integrative AE bioinformatics analysis. A generalized version of CODAE for detection of significant AE
terms for one vaccine or one group of vaccines is outlined in (A). See details in the text. An expanded CODAE solution to analyze and compare AEs
associated with the two vaccination groups is shown in (B). VAERS records were retrieved based on the query criteria of 4 TIVs (Afluria, Fluarix,
Fluvirin, and Fluzone) year 1990–2011 and 1 LAIV (FluMist) year 2003–2011. Parallel analyses of the Proportional Reporting Ratios and Chi-square
significant test were performed on individual AEs to identify enriched and significant AEs in each group. Base level filtration of 0.2% of total number
of reports was also applied to each AEs. AEs that were identified to have PRR . = 2, Chi-square . = 4, and number of reports . = 0.2% of total reports
were then classified based on OAE hierarchical structure. Classification of AEs filtered out AEs that overlapped between the 2 groups.
doi:10.1371/journal.pone.0049941.g001
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the ontology, clarification and definition of terms, and domain
coverage (see detailed discussion in the Discussion section). The
most differential clusters of the adverse events induced by these
two types of influenza vaccines are summarized in Figure 3 and
explained below in detail.
Distinctive underlying biological activities were
associated with the two groups of influenza vaccines
In summary, biological systems highlighted in TIV AEs were
the behavior/neurological system, immune system, and muscle/
nervous systems. LAIV AEs appeared to cluster heavily in the
respiratory system. Behavior/neurological adverse events were
triggered by both TIV and LAIV. However, manual examination
revealed that TIV-induced behavior/neurological adverse events
clustered around muscular, motor and movement disorders, and
LAIV-induced adverse events were mainly pain symptoms in the
head. Figure 3 illustrates the reorganization of TIV- and LAIV-
induced AEs in detail based on the Ontology of Adverse Events
[15]).
The TIV-associated AEs clustered and enriched in movement
and muscle disorders included joint range of motion decreased,
mobility decreased, muscular weakness, Guillain-Barré syndrome
(GBS), paralysis, and hyporeflexia. Another set of TIV-induced
adverse events that was observed exclusively in TIV was edema
(homeostasis and fluid dysregulation) in various parts of the body.
Detailed description of GBS as a TIV-enriched severe AE is
provided in the following section. No inflammatory responses
came up as significant TIV-induced AEs (as opposed to LAIV).
LAIV influenza vaccine triggered other sets of biological
activities in processes of the respiratory system (e.g., sinus
headache, nasal congestion) and respiratory system disorders that
were characterized by inflammation – upper respiratory tract
infection, pneumonia, bronchitis, and nasopharyngitis. These AEs
may be associated directly with the intranasal mode of adminis-
tration of the LAIV. Fifteen distinct adverse events were reported
as over-represented respiratory system disorders. Activities in the
hematopoietic system also suggested evidence in responses to
stimulus related to inflammation. Furthermore, LAIV-induced
adverse events showed a set of activities involved in the gustatory
system and gustatory system-related activities.
Severe AEs are highly enriched in killed-inactivated
influenza vaccine group
Based on FDA’s definition of serious adverse event (SAE) (http://
www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm), SAE
is an adverse event that results in serious or fatal health condition such
as death, permanent damage, or hospitalization. It should be noted
that 2 TIV-specific AEs were SAEs. These included GBS (Chi-square:
1172.79/P-value: 4.99E-257, PRR score: 4.63), and paralysis (Chi-
square: 85.48/P-value: 2.34E-20, PRR score: 2.22). AEs that are
related to these SAEs and also enriched in TIV are hypoaesthesia,
mobility decreased, joint range of motion decreased, musculoskeletal
pain, paraesthesia, and neuralgia.
The association of GBS with influenza vaccination has long
been debated. GBS is a serious immune system disease that has
been reported repeatedly as a rare complication after influenza
vaccine immunization [19,22]. GBS is categorized under immune
system disorder based on cause of disease, or nervous system
disorder based on its biological responses (muscular weakness, and
paralysis). It is notable that a significant number of AE cases
reported as a consequence of administering influenza TIV
vaccines are related to loss of muscle strength in various forms
without the development of GBS. GBS often results in a key
symptom of movement disorder. There are reports of associations
between GBS and TIV influenza vaccines, but the cause-effect
relations remain inconclusive (Table S1).
Another evidence for TIV-associated compromised muscular
system activities was the significantly ranked abnormal electro-
myogram result from TIV AE case reports. Electromyogram
(EMG) is a test that evaluates electrical activity of muscle. Often,
physicians utilize EMG as a method to diagnose GBS and other
muscle-related disorders [23,24]. Observation of both abnormal
lab test result AE (electromyogram abnormal) and physiological
evidence in nervous and muscular disorders pointed toward TIV-
triggered inter-connecting activities in the human body that were
key symptoms of severe AEs (GBS and paralysis).
No SAEs were enriched among the LAIV AEs listed in Table 2.
Pain in the head/neck area exists exclusively on the LAIV list,
which may be explained by the route and method of LAIV
administration (nasal spray). These respiratory system disorder
AEs, for example, include pneumonia (Chi-square: 20.9/P-Value:
4.85E-06, PRR score: 2.01), lobar pneumonia (Chi-square:
124.77/P-value: 5.7E-29, PRR score: 15.77), bronchitis (Chi-
square: 25.84/P-value: 3.71E-07, PRR score: 2.81), and upper
respiratory tract infection (Chi-square: 16.05/P-value: 6.16E-05,
PRR score: 2.22). Operational errors such as expired drug
administered, or inappropriate schedule of drug administration
reported as post-vaccination AE were reported with higher
significance in LAIV.
Figure 2. Venn diagram summary of the three filtering criteria
in each group of vaccines from the pool of 3,582 AEs analyzed
in TIV and LAIV and the universe of 7,520 AEs in the entire
VAERS database. Chi-square value of . = 4 – x2(+), or ,4 – x2(2);
PRR . = 2 – PRR(+), or PRR ,2 – PRR(2); and number of reports .0.2%
of total reported cases (i.e., . = 75 in TIV or . = 8 in LAIV) – count(+), or
else – count(2).
doi:10.1371/journal.pone.0049941.g002
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Table 1. TIV-specific adverse events. 37,621 TIV-induced AE cases were reported.
Adverse Event Count PRR(TIV) Chi-sq (TIV)
AE with an outcome of lab test abnormal
Electromyogram abnormal 107 4.87 248.14
behavior and neurological AE
Dysarthria 91 2.80 75.22
behavior and neurological AE -. movement disorder AE
Paralysis * 181 2.22 105.00
Hyporeflexia (r) 77 2.46 56.62
behavior and neurological AE -. sensory capability AE
Pain 4516 2.12 2475.50
Chills 2286 2.78 2237.97
Pain in extremity 2106 3.40 2944.16
Paraesthesia (r) 1360 2.29 858.59
Hypoaesthesia (r) 1035 2.94 1114.16
Chest pain 725 2.37 492.53
Neck pain 543 2.06 260.28
Throat tightness 449 5.20 1134.22
Musculoskeletal pain (r) 432 4.00 767.24
Palpitations 267 2.70 240.23
Feeling cold 186 2.65 161.93
Skin burning sensation 113 3.04 127.95
Sensation of heaviness 100 2.99 109.56
Shoulder pain 78 3.40 107.20
Neuralgia (r) 77 2.37 52.32
cardiovascular disorder AE
Heart rate increased 397 2.47 297.95
Hypertension 306 2.28 189.79
Blood pressure increased 216 4.11 398.44
Injection site haematoma 175 4.08 318.99
digestive system AE
Dysphagia 299 2.23 175.09
Dry mouth 75 2.68 66.49
eye disorder AE
Eye discharge 135 6.05 406.32
Eye irritation 115 4.62 249.17
hometostasis AE
Pharyngeal edema 256 4.30 503.52
Swollen tongue 158 4.56 336.46
Tongue edema 105 2.51 81.09
Local swelling 88 2.05 40.97
medical intervention (not under ‘adverse event’)
Accidental overdose 83 4.59 177.98
muscle adverse event
Muscular weakness (r) 594 2.89 614.83
musculoskeletal system AE
Laryngospasm 143 2.83 141.06
nervous system AE
Guillain-Barre syndrome * 606 4.63 1321.69
Mobility decreased (r) 161 3.40 221.81
nervous system AE -. mobility decreased AE
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Post-immunization Guillain-Barré Syndrome (GBS) in TIV
recipients occurred at a higher rate per number of
reports than in LAIV
Although enriched in TIV data, GBS is quite an infrequent
incident. Based on our literature review, the incidence rate of GBS
in influenza vaccine recipients is considered rare, approximately 1
in 100,000 [22]. Reports of GBS in LAIV seem to be even rarer.
Post-vaccination GBS was ranked among the over-represented
AEs in all scoring matrices of TIV group (Table 1). In contrast, the
information retrieved via this study showed a small reporting rate
of GBS in the LAIV group that the statistical analysis did not
recognize GBS as LAIV-enriched in Table 2 (ranging from 0–8.37
per 1,000 cases in LAIV in comparison to 2.81–12.1 per 1,000
cases in TIV, data from 2003–2010). However, without consid-
eration of PRR, GBS would pass the criteria of Chi-square and
number of reports in both TIV and LAIV. Manual examination
and cross referencing of input data (VAERS records) confirmed
that the incidence was not manufacturer lot specific. Investigation
of the numbers of GBS cases reported per year in each group
suggested that LAIV was less likely to be associated with post-
immunization GBS than TIV (Figure 4).
To further investigate the reporting rate of GBS and GBS-
related AEs among the patients who reacted to the trivalent
seasonal influenza vaccines (both TIV and LAIV), we first tried to
determine whether or not these reported incidences were specific
to the year of reports. Figures 5A and 5B display the percentage
ratio of the reported cases of TIV- and LAIV-induced GBS and
other related symptoms per calendar year of reports. These AEs
include symptoms resulting in movement and muscular disorders:
paralysis, paraesthesia, hypokinesia, musculoskeletal pain, joint
range of motion decreased, myasthenic syndrome, mobility
decreased, neuropathy, and hypotonia. We extended the scope
of GBS examination to include other muscular and nervous
disorders in an attempt to avoid the possibility of overlooking AEs
that were closely related to GBS. These cases would have been
ignored as non-important when focusing on GBS alone. Figure 5C
shows the combined percentage of these selected AEs as one
cluster based on year of reports. The denominator for the
individual year calculation is the number of cases reported in that
particular year. Figures 5 (A–C) have pointed towards the over-
represented incidence rate of GBS and GBS-related AEs in TIV.
Since LAIV surveillance data became available only in late
2003 after FluMist was released, the comparison of TIV and LAIV
by Chi-square significance test against each other could only be
calculated from 2004 on. Table 3 summarizes TIV’s probability
value of how much more GBS and GBS-related AEs are
represented in comparison to LAIV. The results show that all
but three P-values are smaller than 0.05, signifying that GBS and
GBS-related AEs are more enriched in TIV. One of those three
years is a statistical artifact since the raw number of occurrences in
LAIV is equal to 0 (partial year 2003). Figures 6A and 6B plot the
age-range percentage ratio in which each examined AE occurred
based on the total sample size in this study of TIV and LAIV,
respectively. The results indicate that all GBS and GBS-related
AEs occurred at a higher rate in the early age group (0–5 years)
with another trend of increasing occurrence in middle to later age
range (40–75) (Figure 5A). There was no suggestion of age pattern
in GBS and GBS-related AE occurrences in the LAIV group
(Figure 5B).
Age range distribution of influenza vaccine-associated GBS and
other related symptoms is depicted in Figure 6. Figure 6A focuses
on TIV recipients. All but one selected AEs (paraesthesia) followed
the expected age range of the populations who were more at risk of
GBS (young children and the elderly). Figure 6B describes the age
distribution of LAIV recipients who developed the same symptom
AEs as those in Figure 6A. Unlike TIV recipients, the age
distribution of LAIV recipients is scattered across all age ranges.
The comparison of the age distributions in these two groups
indicates that TIV (but not LAIV)-associated GBS occurrence
follows a similar trend of GBS occurrence in the influenza vaccine
recipients who are young children and elderly [25,26,27,28], while
LAIV-associated GBS cases occur in all age ranges as observed in
general cases [29].
Meta-analysis of influenza vaccine AE reports suggests
association between GBS and TIV (but not MIV)
Our meta-analysis of influenza vaccine AE reports suggests that
monovalent inactivated influenza vaccines are associated with
fewer reports of SAE compared to trivalent inactivated influenza
vaccine (Table 4). The majority of peer-reviewed publications on
influenza vaccine-associated GBS in recent years were studies of
monovalent influenza vaccines. Of 19 influenza vaccine-related
GBS from our literature survey (Table 4), five concluded elevated
incidence rate or reporting ratios or GBS as the most common
reported SAE, four described inconclusive correlation of GBS to
influenza vaccination, and 10 stated that there were no positive
correlations of GBS to influenza vaccine immunization. The
studies in this literature survey were performed on the set of both
Table 1. Cont.
Adverse Event Count PRR(TIV) Chi-sq (TIV)
Injected limb mobility decreased (r) 561 4.72 1253.55
Joint range of motion decreased (r) 317 4.36 635.69
respiratory system AE
Dyspnea 2088 2.18 1180.96
skin adverse event
Flushing 403 3.00 447.05
Eye pruritus 168 9.06 754.39
Hot flush 109 3.37 147.90
Note:
* = serious adverse event,
(r) = related to serious adverse event.
doi:10.1371/journal.pone.0049941.t001
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Table 2. LAIV-specific adverse events. 3,707 TIV-induced AE cases were reported.
Adverse Event Count PRR(LAIV) Chi-sq(LAIV)
AE with an outcome of lab test abnormal
Influenza serology positive 32 28.46 715.61
Chest X-ray abnormal 24 4.00 51.89
Blood creatine phosphokinase increased 19 3.96 40.33
Blood glucose increased 18 2.25 11.95
Urine analysis abnormal 15 2.78 16.43
Computerised tomogram abnormal 13 2.23 8.44
Nuclear magnetic resonance imaging brain abnormal 13 2.74 13.77
Electrocardiogram abnormal 11 2.36 8.27
Neutrophil percentage increased 11 3.00 14.13
Urine ketone body present 10 7.11 49.64
Lymphocyte percentage decreased 9 3.13 12.51
behavior and neurological AE
Headache 383 2.22 257.06
Fatigue 159 2.16 97.17
Abdominal pain upper 54 3.49 92.50
Ear pain 22 3.01 28.48
Migraine 21 2.54 18.85
Abdominal discomfort 15 3.38 24.20
Burning sensation 15 2.25 9.97
Sinus headache 14 18.72 208.53
VIIth nerve paralysis 11 11.08 93.29
Facial paresis 9 5.37 30.53
Ataxia 8 3.50 13.72
cardiovascular disorder AE
Epistaxis 71 14.71 823.81
Pericarditis 9 3.97 19.16
digestive system AE
Retching 12 3.27 18.19
Dry throat 10 10.32 78.17
gustatory system AE
Throat irritation 17 3.05 22.55
errored drug administration
Expired drug administered 503 90.04 28507.94
Inappropriate schedule of drug administration 169 4.15 390.47
eye disorder AE
Photophobia 17 2.66 16.90
Eye irritation 10 3.41 16.37
Visual impairment 9 3.05 11.92
homeostasis AE
Swelling face 44 2.51 38.58
Eyelid edema 13 2.03 6.49
immune system disorder
Immunization reaction 9 2.43 7.30
infection adverse event
Croup infectious 11 9.58 78.80
injury and procedural complication AE
Pregnancy test positive 10 3.21 14.60
medical intervention
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trivalent and monovalent influenza vaccines. All five studies
indicating that GBS had a positive correlation with influenza
vaccine immunization were based on trivalent influenza vaccines.
Discussion
To study vaccine AEs associated with a specific vaccine, two
types of immunization population denominators can be used. One
is the total number of people immunized for one single vaccine in
a region during a given period. Another type of population
denominator is the total number of people who reported AE cases
to VAERS for all vaccines in a region during a given period. Like
other VAERS bioinformatics studies, our approach uses the
second immunization population denominator [18]. Although the
VAERS spontaneous reporting system lacks a true control (i.e.,
people randomized to receive a placebo), our bioinformatics
method analyzed AEs associated with a vaccine using all other
vaccines as a quasi-control group for comparison [18].
In our study, we did not directly compare TIV vs. LAIV.
Essentially, we tested all the AE case reports associated with TIV
or LAIV independently against the whole VAERS database. Then
the results of significantly enriched AEs in each group were
identified using our combinatorial bioinformatics analysis pipeline.
Our CODAE pipeline contains three methods for detection of true
AE signals: PRR, Chi-square, and filtering based on the number of
reports. After the significance of individual AEs associated with
TIV or LAIV was identified, we compared the TIV and LAIV-
enriched AEs through two ways. The first one is qualitative (i.e.,
presence or absence) comparison between the two AE lists. The
second method is through quantitative comparison, i.e., comparing
the ratios of TIV (or LAIV)-associated AE case number over the
total number of the same AE in the whole VAERS database. In
the end, we used ontology-based methods to classify and compare
significantly enriched AEs in each group.
We hypothesized that the AE differences in the two sets of
recipients (TIV vs. LAIV) emerged from different immune-
response pathways induced by each type of vaccine. Our study
suggests that the combinatorial CODAE bioinformatics approach
can overcome the complex challenges in public post-vaccination
event record data. The strategy of this study resolves the issue of
high-noise data, especially when these data contain high-value
hidden knowledge that can be evaluated by robust statistical tests.
Table 2. Cont.
Adverse Event Count PRR(LAIV) Chi-sq(LAIV)
Drug exposure during pregnancy 77 3.90 159.92
Accidental exposure 30 20.56 490.83
Vaccination error 13 30.19 306.90
Underdose 11 11.64 98.65
Drug administration error 9 5.81 34.07
muscle disorder AE
Bronchospasm 8 4.60 21.52
respiratory system AE
Rhinorrhea 210 9.47 1493.03
Nasal congestion 177 11.64 1593.58
Sneezing 53 10.78 436.15
Pneumonia 43 2.01 20.90
Sinusitis 43 5.92 167.24
Asthma 35 2.07 18.45
Respiratory tract congestion 32 7.68 175.14
Upper respiratory tract infection 25 2.22 16.05
Nasopharyngitis 25 4.08 55.69
Bronchitis 23 2.81 25.84
Sinus congestion 13 8.49 80.57
Nasal discomfort 12 47.77 422.18
Stridor 10 3.82 19.93
Postnasal drip 10 20.90 166.27
Lobar pneumonia 10 15.77 124.77
skin adverse event
Pruritus generalized 15 2.94 18.45
Rash pustular 15 2.19 9.29
Henoch-Schonlein purpura 15 8.20 89.03
social behavior AE
Activities of daily living impaired 23 2.36 17.29
Impaired work ability 8 3.96 16.94
doi:10.1371/journal.pone.0049941.t002
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It is crucial to identify background information, as some AEs are
common to many vaccines. Because the number of reports in
VAERS database is large (616,215 cases, 75 vaccines), background
information is not sensitive to minor change or adjustment such as
removing reports from one or two vaccines from the studied
sample set. One novel feature of our combinatorial workflow
(summarized in Figure 1) is its application in comparing two
cohort sets of AEs. Another novelty of our approach is the use of
the OAE for categorization of identified AEs. While this
combinatorial workflow was applied specifically to VAERS data,
the concept can also be adapted and applied to other questions in
the Translational Informatics domain. Furthermore, the prelim-
inary result in the form of flat list (i.e., the simple text file of
records) may be informative at an individual AE level. However, it
is difficult to examine the flat list to identify the underlying
biological systems when the system is composed of multiple
interactions among multiple participating AEs. It is challenging to
draw any connections between biological processes while the
significant individual AE terms scatter across various different
biological functions and systems. Examining these AEs based on
their score rankings along with reorganizing results by their
semantic similarity and functional relevance leads to a better
representation of data that can overcome this issue. Analysis of
alignment of semantic similarity to a reference structured
controlled vocabulary is discussed below.
The results indicated that out of .37,000 TIV-associated AEs,
48 met the threshold for inclusion in the analysis, while of roughly
3,700 LAIV AEs, 68 met the threshold. Although this seems
counter intuitive or surprising, TIV-associated AEs include two
severe AEs (GBS and paralysis). Many other TIV-associated AEs
are also related to neurological and muscular disorders, which can
be considered as mild symptoms that can be further progressed to
more severe symptoms including GBS and paralysis. GBS is
classified as a syndrome that has indication of multiple symptoms.
On the other hand, LAIV vaccination appears to induce many
mild symptoms. No severe LAIV AEs that pass our thresholds has
been detected.
The age patterns associated with the reports of GBS and other
GBS-related disorders between patients immunized with TIV and
LAIV are quite different (Figure 6). For TIV-associated GBS
cases, the age range of 45–79 (34 years) has a high peak of . = 1
per 1,000 TIV AE case reports. The highest rate is approximately
2 cases per 1,000 TIV AE case reports at the age range of 55–69.
For LAIV, the age ranges of 5–9 has slightly higher than 1 per
1,000 LAIV AE case reports, and the age range of 20–24 is
associated with approximately 2 per 1,000 LAIV AE case reports.
It appears that TIV is associated with GBS in a longer period of
time and primarily occurs in adult and senior age, and LAIV-
associated GBS primarily occurs in young age. Based on these
observations, to better prevent GBS, it might be a good strategy to
use TIV for young age patients and LAIV for adults and seniors.
Incidents of serious AEs are not always easy to detect in terms of
population statistics as they may require a long period of
observation. Therefore, the detection and confirmation of such
incidents can be inconclusive or take a long time. Examples of
time-consuming observations of vaccine post-marketing AEs
include GBS after 1976 Swine Flu to 2009 A/H1N1 influenza
vaccine campaigns [1,19], anthrax vaccine adverse events (VAEs)
studied from 1990 to 2007 [30], and 1990–2007 measles vaccine
adverse effects studied in the Ivory Coast [31]. Although the 1976
incidence of GBS following Swine Flu vaccination was detected in
real time, debate and discussion of the incidence remained
inconclusive.
Figure 3. Diagram of AE counts grouped by related symptoms. Behavior/neurological system contains the most adverse events distributed in
two groups of vaccines (40 adverse events; 25 in TIV, 15 in LAIV) but the clusters are significantly different in processes. TIV’s behavior/neurological
AEs are much more closely related to those of muscle and movement disorder while LAIV’s behavior/neurological AEs cluster around pain in the
head. Respiratory system AEs is listed as the most significant cluster in LAIV group with 16 AEs. Full listing can be found in Table 1 (TIV) and Table 2
(LAIV).
doi:10.1371/journal.pone.0049941.g003
Figure 4. Comparison of reporting rates of GBS cases associated with TIV and LAIV administrations. The Y-axis is the number of GBS
cases per 1000 case reports for either TIV or LAIV group. The comparison starts the year when both groups have available data in VAERS.
doi:10.1371/journal.pone.0049941.g004
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One interesting finding from this study was the occurrence of
GBS in TIV recipients. There have been many controversial
results with regard to the post influenza vaccination incidents,
whether or not influenza vaccines induce GBS in the recipients.
When considering specific subgroups of influenza vaccines (TIV
versus LAIV), our analysis suggests that compared to LAIV, TIV
is more strongly correlated with GBS (Table 3). Haber et al.
concluded that the occurrence of GBS in influenza vaccine
recipients was merely temporal association, and the causal
association was not implicated with any solid evidence [1].
Furthermore, Haber et al. had challenged the study of Souayah
et al. [32] that used the VAERS dataset by pointing out the
VAERS limitation due to lack of standardized case follow-up.
Haber et al. also argued that influenza vaccine-associated GBS
incidence should be determined by influenza season rather than
calendar year [33]. After a careful examination of the data, we
found that pooling the entire VAERS dataset with our method-
ology could overcome the issues of omitted data or reporting
intervals. Whether or not the reporting interval was based on the
season or calendar year, overall incidence rate was not dependent
on any one particular year or season. The number of post-
influenza-vaccine GBS confirmed by neurologists in VAERS
(1995–2003) as investigated by Haber et al. was observed to be
82%. This observation, when combined with additional data that
became available in the later years, was still statistically significant
as shown in a larger dataset such as the dataset used in this study.
Souayah et al.’s study in 2009 remained firm in their conclusion of
influenza vaccine-associated GBS with significant incidence rate
[34]. Evans et al. also associated GBS and rare adverse events with
influenza vaccine by conducting a comparative study of the novel
influenza (swine flu) prepandemic data in 2009 to 1976 National
influenza Immunization Program data [19]. Our study found that
Souayah’s and Evans’ GBS association to influenza vaccines held
true only when considering TIV, not LAIV. Furthermore, in a
recent study by Moro et al., severe adverse events including GBS
were implicated in the TIV high-dose recipients [35]. To the best
of our knowledge, our systematic comparative study is the first to
suggest that severe adverse events included GBS are more likely to
be associated with trivalent (killed) inactivated influenza vaccine
(TIV), but not live attenuated influenza vaccine (LAIV) or
monovalent inactivated influenza vaccine.
As indicated in our meta-analysis, six out of 19 influenza
vaccine-associated GBS reports show increased incidence rate of
GBS ([36,37,38,39,40,41]) (Table 4). In all these five studies that
concluded the association between GBS and influenza vaccines,
trivalent inactivated influenza vaccine (TIV) vaccination, instead
of monovalent inactivated influenza vaccine (MIV) administration,
was used. This phenomenon suggests no detected association of
GBS to MIV vaccination. It is likely that the mix of different
inactivated influenza strains in the TIV may increase the chance of
obtaining GBS. However, these studies were usually based on
individual case investigation with a relatively small cohort. Further
investigation on the subject of monovalent versus trivalent
inactivated influenza vaccines as the trigger of post-immunization
GBS is required before conclusion can be made.
Even though the safety of TIVs is generally accepted at the
population level, our analysis points towards LAIV as an
alternative immunization that is less likely for the recipient to
develop severe AEs such as GBS or paralysis. However, although
the number of reported SAE cases associated with LAIV is very
small that GBS and paralysis were not statistically enriched in
LAIV group, the occurrences of LAIV-associated SAEs should still
be investigated carefully. While GBS and paralysis (as categorized
to be severe adverse events) were statistically enriched in the TIV
group, for further study, the weighted-AE scoring method should
be applied in future studies to properly address the issue of SAEs.
All SAEs should automatically rank high in the significance of AE
for both cohorts (TIV and LAIV).
Utilizing data from Vaccine Safety Datalink project, Lee et al.
conducted a weekly sequential analysis of potential influenza
vaccine adverse events from 9.2 million members in eight U.S.
medical care organizations from November 2009 to April 2010
[22]. Both trivalent and monovalent seasonal killed and live
attenuated influenza vaccines over a long observation period were
examined. In total, 15 cases of GBS from 1,345,663 monovalent
killed influenza vaccine (MIV)-vaccinated individuals were iden-
Figure 5. Comparison of yearly report distributions of GBS and GBS-related adverse events associated with TIV and LAIV. LAIV was
recently released and therefore data available are from 2003 onward. The raw number of occurrences was scaled to percentages by the number of
reports in each year. The percentages of yearly case reports of GBS and other GBS-related symptoms associated with TIV and LAIV are displayed in (A)
and (B), respectively. The combined percentages of GBS and related AEs associated with TIV and LAIV are depicted in (C).
doi:10.1371/journal.pone.0049941.g005




total cases reported in
that year (TIV)
# GBS and GBS-related
AEs(LAIV)
total cases reported in
that year (LAIV)
P-Val (selected AEs occur
independently of TIV)
2003 150 1790 0 34 7.81E-02
2004 163 2187 9 339 1.10E-03
2005 278 2842 13 198 1.37E-01
2006 244 2430 12 172 1.92E-01
2007 292 3165 2 180 1.84E-04
2008 321 3725 14 660 7.01E-09
2009 498 5231 36 1272 6.46E-15
2010 625 7165 26 797 9.44E-08
2011 134 1021 0 75 8.12E-04
Note: GBS-related muscle and neurological AEs studied here included musculoskeletal pain, paraesthesia, and muscular weakness.
doi:10.1371/journal.pone.0049941.t003
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tified following MIV administration, 23 out of 2,741,150 cases
after TIV, and zero out of 157,838 cases after LAIV. This study
found that the GBS incidence after TIV administration was
slightly lower than that after MIV administration. The incidence
rates of GBS after both trivalent and monovalent killed influenza
vaccines was approximately 1 in 100,000, which was not
considered as statistically significant signals for GBS [22]. This
study has also been included in our meta-analysis (Table 4). The
result of this study does not change our meta-analysis conclusion
that GBS was associated with TIV rather than MIV vaccination.
Interestingly, zero cases of GBS were identified in LAIV-
vaccinated patients, supporting our conclusion that LAIV may
be safer than TIV in terms of induction of GBS vaccine adverse
events. However, the sample size (157,838) of LAIV-vaccinated
patients is relatively low compared to MIV- or TIV-vaccinated
patients in their study. Our conclusion was drawn by combina-
torial statistical analysis of VAERS case report data. Using all
available VAERS case report data, our combinatorial method
compares TIV- or LAIV-associated vaccine adverse events (VAEs)
with VAEs associated with other vaccines. Our results suggest
statistically significant association between TIV and GBS and
paralysis, while LAIV shows no statistical evidence of correlation
to GBS. Further studies to verify our conclusion of the higher
safety of LAIV over TIV in terms of GBS induction are required.
One novel finding from our combinatorial bioinformatics
analysis of influenza vaccine adverse events is that beside the
relatively higher reporting rate of GBS and paralysis severe
adverse event (SAE) cases associated with TIV than LAIV, TIV
vaccination was also associated with a set of other mild
neurological and muscular adverse events (e.g., paraesthesia,
hyporeflexia, musculoskeletal pain, and neuralgia) (Table 1).
Although these symptoms are not considered SAEs, it is likely
that these symptoms are signals of potential future GBS and
paralysis SAEs due to their common neurological and muscular
roots. The non-severe symptoms in some healthier patients may
suggest signs of severe symptoms in other weaker patients. We
hypothesize that the molecular interaction networks underlying
these neurological and muscular adverse events, whether it is
severe (i.e., GBS and paralysis) or non-severe (i.e., paraesthesia and
hyporeflexia), are the same or similar at least at the early stage of
these adverse events. By exploring these interaction networks, we
can potentially identify the mechanisms of severe VAEs.
Further analysis of TIV- and LAIV-induced AEs by reorganiz-
ing into an ontological structure with reference to other
community-accepted ontologies reveals certain challenges that
need to be properly addressed. We have clustered AEs of each
group of vaccines to COSTART (1995) (the foundation vocab-
ulary that MedDRA was built upon) with an embedded
Figure 6. Comparison of case report distributions of GBS and GBS-related adverse events associated with TIV and LAIV based on
age using the data from 2003. (A) In TIV, all but one selected AEs (paraesthesia) followed the expected age range of the populations who were
more at risk of GBS (young children and the elderly). (B) In LAIV recipients, age distribution is scattered across all age ranges.
doi:10.1371/journal.pone.0049941.g006
Adverse Events of Influenza Vaccines

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adverse Events of Influenza Vaccines































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adverse Events of Influenza Vaccines
PLOS ONE | www.plosone.org 16 November 2012 | Volume 7 | Issue 11 | e49941
hierarchical structure available on BioPortal (http://bioportal.
bioontology.org/visualize/40390). We found that the COSTART
hierarchical structure might not be a suitable term reorganization
reference as the COSTART/MedDRA structure lacked a specific
definition on which the aspect of this hierarchical tree was based.
It was not clear if the hierarchy was defined by biological
processes, or anatomy of the body. Hypothetically, COSTART/
MedDRA is a comprehensive dictionary of adverse event
descriptors; however, it was not created for the purpose of
computation and the structure organization may not be fully
equipped for ontological machine processing. Many concepts in
COSTART listed synonyms that were not true synonyms. For
example, in COSTART, sinus headache was defined to be
synonymous to headache, and infection upper respiratory was
defined to be synonymous to infection. Many examples of this kind
of synonym error occur throughout the COSTART hierarchy.
Another major issue in using COSTART as an ontological
reference was that COSTART contained duplicate classes that
caused ambiguity in many situations. For example, ear disorder
was a child under a parent class of the same class name ear
disorder, hemorrhage was a child of parent class haemorrhage
[same word], and hypotension was a child of parent class shock
syndrome which was, in turn, a sibling class of another concept
that also has class identifier of hypotension. In an improvement of
COSTART that results in MedDRA (version 12, released on 03/
01/2009), terms are reorganized in a more comprehensive
hierarchical structure, but further issues of one asserted class
falling under multiple asserted parent nodes, or ambiguous
synonym listings remain problematic. Examples of these classes
can be found in class properties of Migraine, Migraine headache,
Sinus headache, and other AEs throughout MedDRA (Figure S3).
We then explored another clinical ontology of SNOMED
Clinical Terms (Version 07/31/2010) to find an alternative for AE
term reorganization for the purpose of recognizing AEs based on
biological relevance (Figure S4). We found that, while SNOMED
CT was thoroughly defined with the most detailed information of
anatomical and physiological description, this ontology still may
not be the best alternative for such purposes. The comprehensive
organization of terms in SNOMED CT resulted in a structure that
did not provide an apparent clustering for term recognition based
on biological process, because classes at the individual AE level
(leaf nodes) were scattered across the ontology due to the nature of
very detailed parental subclasses.
From the investigation of MedDRA and SNOMED CT as a
reference controlled vocabulary, neither suited the purpose for
such reference. Although MedDRA may not be the best
nomenclature system for the purpose of AE reporting, it has been
referenced in VAERS for many years. Therefore, to be able to
mine for discovery within VAERS records, we must find methods
to process and interpret VAERS data in an efficient way that
discovers the knowledge embedded within it. Also, sometimes,
MedDRA terms that are reported in VAERS fall into many
semantic types in SNOMED CT, namely Body structure, Clinical
finding, Procedure, Special concept, or Qualifier value. Such
terms are within the same semantic type and there are also sub-
structures that may further divide MedDRA terms into many
separate groups. One example scenario that appeared in this
situation is how Edema was described and categorized on the two
ontologies. In SNOMED, Edema is a Clinical finding while
Edema of pharynx is a child of Disorder characterized by edema,
Disorder characterized by edema is a subclass of Disease, while
Disease is a Clinical finding. This, in turn, resulted in Disease that
was a sibling of class Edema while containing a child of a child of
class Edema of pharynx. This separation by different semantic
types occurred frequently in SNOMED-CT.
In this study, we have shown that the application of OAE can
provide insights into underlying processes that may be overlooked
or hard to detect without efficient prior-knowledge structural
hierarchy (Figure 3 and Figure S2). Our combinatorial bioinfor-
matics approach integrates different biostatistics analysis methods
with ontology-based AE term classification. This method can also
be modified to answer adverse event questions in different areas,
for example, drug adverse events. It is noted that current study
only used a part of the OAE features. Different from MedDRA
and SNOMED-CT that represent adverse event outcomes, the
OAE targets the representation of the whole process starting from
the medical intervention (e.g., vaccination) and ends with the
discovery of the adverse event outcomes. Therefore, OAE
provides a platform to examine in detail all the variables that
can affect the results, such as patient age and sex, vaccination dose
and route, and time interval between vaccination and the outcome
of symptoms. Different from the original version of the Adverse
Event Ontology (AEO) [15], the term ‘‘adverse event’’ defined in
current OAE does not assume causal relation between an adverse
event outcome and a medical intervention. The causal relation is
now defined in an OAE term ‘‘causal adverse event’’. One major
task of the OAE research is to identify or predict the causal
association based on various datasets including clinical adverse
event reports.
Gleaning and cleaning real-world clinical data with this approach
also introduces a novel hypothesis generator tool to aid
translational informatics as the results are supported by statistical
evaluation and validation of the findings. The method is designed
to be discovery-driven rather than the traditional research
hypothesis-driven approach. Two possible hypotheses that are
derived from this post-vaccination adverse event investigation
could be: (1) Hypothesis 1: TIV induces the occurrence of GBS
that may be explained by the trigger in behavioral & neurological
processes due to their possible shared gene interaction networks,
and (2) Hypothesis 2: LAIV is more likely to trigger respiratory
inflammatory response than TIV due to its mode of administra-
tion.
Conclusions from this study speak to the interest of personalized
medicine of individuals. As a recent study by Liang et al. indicates
the occurrence of GBS as below the background rate of severe
adverse event induced by influenza vaccine [42], those observa-
tions were made on the whole population of influenza vaccine
recipients including the majority who did not develop any major
post-vaccination complication. Our study, in contrast, focuses on
the sub-population of those whose cases have been submitted to
VAERS as having a post-vaccination complication. This differ-
ence in the focused population group may lead to the hypothesis as
to which molecular or genetic variation of the person can cause the
occurrences of influenza vaccine-induced severe AEs.
Supporting Information
Figure S1 Signal curves to determine the data cutoff for
TIV and LAIV analysis. (A) Cutoff signal curve for TIV cutoff
signal curve. (B) Cutoff signal curve for LAIV cutoff signal curve.
Rendering and visualization of this plot was based on the adjusted
display in MS Excel 2011 version 14.1.4. Some AE labels, though
existed in dataset, were omitted on the plot.
(PDF)
Figure S2 Classification of TIV- and LAIV-enriched
vaccine adverse events using OAE. TIV- and LAIV-enriched
vaccine adverse event terms (MedDRA terms) identified in this
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study were mapped to OAE terms. The hierarchical structure of
OAE was used to identify the parent terms and classify these of
these adverse event (AE) terms.
(PDF)
Figure S3 Classification of TIV- and LAIV-enriched
vaccine adverse events using MedDRA. TIV- and LAIV-
enriched vaccine adverse event terms (MedDRA terms) identified
in this study were classified using the hierarchical structure of
MedDRA.
(PDF)
Figure S4 Classification of TIV- and LAIV-enriched
vaccine adverse events using SNOMED-CT. TIV- and
LAIV-enriched vaccine adverse event terms (MedDRA terms)
identified in this study were mapped to SNOMED-CT terms. The
hierarchical structure of SNOMED-CT was used to classify these
terms.
(PDF)
Table S1 Calculation of PRRs for vaccine adverse
events. Background information of Proportional Report Ratio
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